Table 1.

Trials of tyrosine kinase inhibitors in patients with metastatic differentiated thyroid cancer.

Agent	Motesanib [7]	Axitinib [8]	Sorafenib [9]	Sorafenib [10]	Sorafenib [11]	Sorafenib [12]	Sunitinib [13]	Sunitinib [14]	Pazopanib [15]	Lenvatinib [16]
Mechanism	VEGFR, PDGFR, Kit	VEGFR PDGFR, Kit	BRAF, VEGFR	BRAF, VEGFR	BRAF, VEGFR	BRAF, VEGFR	VEGFR PDGFR, Kit, FL3, RET	VEGFR PDGFR, Kit, FL3, RET	VEGFR PDGFR, Kit	VEGFR1-3, FGFR1-4, RET, KIT PDGFRβ
N enrolled	93	60	30	56	31	34	33	43	37	58
Histology (DTC), n	93	45	27	52	27	19	28	37	37	58
Median PFS	40 wks	18 mos	79 wks	15 mos	58 wks	12 mos	12.8 mos	NR	11.8 mos	12.6 mos
Outcome (RECIST)
CR%	0	0	0	0	0	0	3	0	0	0
PR%	14	31	23	12	25	20	25	13	49	50
SD%	67	42	53	65	34	48	50	68	46	46

BRAF: B isoform of Raf kinase; DTC: differentiated thyroid cancer; PDGFR: platelet-derived growth factor receptor; VEGFR: vascular endothelial growth factor receptor; NR: not reported; mos: months; wks: weeks; RECIST: response evaluation criteria in solid tumors; CR: complete response; PR: partial response; SD: stable disease; PFS: progression-free survival time.

Note: vandetanib is not shown in the table.